Skip to Content
Søg Menu
Vi dækker

ESMO I European Society for Medical Oncology

Dansk Aften ESMO 2025 – Berlin

Du har nu mulighed for at tilmelde dig til Dansk Aften ESMO 2025 i Berlin. Mød dine kolleger og få en opsummering af nyheder og highlights fra kongressen – efterfulgt af netværk og middag.

ESMO 2024

PD-1 Inhibitors Have Shown Remarkable Efficacy

  • / BestPractice Nordic

Highlights fra ESMO 2024

Louise Wichmann Matthiessen

Highlights: Det kliniske landskab for brystkræft efter ESMO 2024

/ Louise Wichmann Matthiessen
ESMO24Brystcancer Play the Video
Dag Rune Stormoen

Highlights fra ESMO 2024: Non-muskelinvasiv, muskelinvasiv og metastatisk / lokal-avanceret blærecancer

/ Dag Rune Stormoen
ESMO24Blærecancer Play the Video
Morten Mau-sørensen

Highlights fra ESMO 2024 for øvre gastrointestinal cancer

/ Morten Mau-Sørensen
ESMO24Gastrointestinal cancer Play the Video
Jens Benn Sørensen

Highlights fra ESMO 2024 om lungecancer

/ Jens Benn Sørensen
ESMO24Lungecancer Play the Video
Charlotte Aa. Hasund

ESMO 2024: Highlights for ovariecancer og endometricancer

/ Charlotte Haslund
ESMO24Gynækologisk cancer Play the Video
Rasmus Friis

Fejring af langtidsdata for behandling af metastatisk malign melanom – og døren til neoadjuverende behandling er ved at åbne sig

/ Rasmus Blechingberg Friis
ESMO24Melanom Play the Video

Top 4 mest sete MEDtalks fra ESMO 2024

Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

/ Onkologi / Josep M. Llovet

ESMO 2024: Highlights for ovariecancer og endometricancer

/ Onkologi / Charlotte Haslund

Enzalutamide plus Radium223 Treatment as First-Line for mCRPC in a Nordic Perspective

/ Onkologi / Gedske Daugaard

Highlights fra ESMO 2024 for øvre gastrointestinal cancer

/ Onkologi / Morten Mau-Sørensen

Mere fra ESMO 2024

Louise Wichmann Matthiessen

Highlights: Det kliniske landskab for brystkræft efter ESMO 2024

/ Louise Wichmann Matthiessen
ESMO24Brystcancer Play the Video
Silke Gillessen

PEACE-3 study: Enzalutamide and Ra-223 as First-Line Therapy for mCRPC

/ Silke Gillessen
ESMO24Prostatacancer Play the Video
Rasmus Friis

Fejring af langtidsdata for behandling af metastatisk malign melanom – og døren til neoadjuverende behandling er ved at åbne sig

/ Rasmus Blechingberg Friis
ESMO24Melanom Play the Video
Hent flere

Abstracts fra ESMO 2024

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

  • / BestPractice Nordic

Several Unsettled Questions About Breast Cancer Treatment

/ Onkologi / BestPractice Nordic

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ Onkologi / BestPractice Nordic

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ Onkologi / BestPractice Nordic

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ Onkologi / BestPractice Nordic

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ Onkologi / BestPractice Nordic
Se oversigt

Highlights fra ESMO 2024: Non-muskelinvasiv, muskelinvasiv og metastatisk / lokal-avanceret blærecancer

/ Almen praksis / Dag Rune Stormoen

Hope and Disappointment for Ovarian Cancer Treatment

/ Onkologi / Mansoor Raza Mirza

Significant Updates on Neoadjuvant Treatments for Stage 3 Melanoma

/ Onkologi / Marco Donia

Efficacy and Safety of Targeted Therapy vs Standard of Care in Patients with Solid Tumors

/ Onkologi / Andrea Botticelli

Highlights fra ESMO 2024 om lungecancer

/ Onkologi / Jens Benn Sørensen

Urgent Need for More Knowledge About Quality of Life and Symptoms in Cancer Patients over 80 Years of Age

/ Onkologi / Elisabeth Grov Beisland
Se oversigt

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

/ Onkologi / Henrik Grönberg

The Role of ctDNA in Precision Oncology – New Data from the IMPRESS-Norway Study

/ Onkologi / Ingrid Dyvik

ctDNA-Guided Immunotherapy Shows Promising Results to Reduce Overtreatment and Improve Outcomes for Patients with Bladder Cancer

/ Onkologi / Jørgen Bjerggaard Jensen

ESMO 2024: Perspektivering af nye data for behandling af brystcancer med trastuzumab deruxtecan

/ Onkologi / Louise Wichmann Matthiessen

Høydepunkter fra ESMO 2024 om lungekreft

/ Onkologi / Bjørn Henning Grønberg

LBA35: Positive Efficacy for Eftilagimod plus Pembrolizumab in Patients with Head and Neck Squamous Cell Carcinoma

/ Onkologi / Claus Andrup Kristensen
Se oversigt

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungecancer

The Ultimate Proof That Immunotherapy Can Be Curative for Metastatic Malignant Melanoma

/ BestPractice Nordic
ESMO24Melanom

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
ESMO24ProstatacancerNyrecancerBlærecancer
Hent flere

ESMO 2023

Endometriecancer: PD-L1 hæmmer i kombination med PARP-hæmmer reducerer signifikant progressionsfri overlevelse

/ Anja Ør Knudsen
ESMO23Brystcancer

KEYNOTE-522 viser forsat forbedret event-fri overlevelse for patienter med triple-negativ brystcancer

/ Ann Søegaard Knoop
ESMO23Brystcancer
Peter Schmid

Pembrolizumab + Chemotherapy: a New Standard of Carefor Triple-Negative Breast Cancer

/ Peter Schmid
ESMO23Brystcancer Play the Video

Utvalgte ESMO 2023 Høydepunkter: Prostatakreft

/ Onkologi / Daniel Heinrich

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Onkologi / Kristina Lindemann

Two New Potential Game-Changers in the Treatment of Gastroesophageal Cancer

/ Onkologi / Lene Bæksgaard

ESMO 2023: Dobling av overlevelsesraten ved innovativ behandling for metastatisk blærekreft

/ Onkologi / Daniel Heinrich

Potential New Standard of Care for Locally Advanced Cervical Cancer

/ Onkologi / Kristina Lindemann

ESMO 2023 • Meet the experts

Get access
Mansoor Raza Mirza

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

/ Mansoor Raza Mirza
ESMO23Gynækologisk cancer Play the Video
Peter Meldgaard

Spændende data om adjuverende behandling til ALK-translokerede patienter og lavstadiet lungecancer

/ Peter Meldgaard
ESMO23Lungecancer Play the Video
Ellinor Haukland

Enabling Patient Empowerment Through Digital Monitoring

/ Ellinor Christin Haukland
ESMO23Patientinddragelse Play the Video
Marco Donia

ESMO 2023 Highlights: Developments in Melanoma

/ Marco Donia
ESMO23Melanom Play the Video
Jonathan Spicer

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Jonathan Spicer
ESMO23Lungecancer Play the Video
Henrik Grönberg

Prostate Cancer: Adaptive, Biomarker-Driven Platform Trial Shows That New Hormonal Agents Have Better Efficacy for mCRPC

/ Henrik Grönberg
ESMO23Prostatacancer Play the Video

Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

/ Shannon Westin
ESMO23Gynækologisk cancer Play the Video
Mansoor Raza Mirza

New Treatment Possibilities for Patients with Recurrent or Primary Advanced Endometrial Cancer

/ Mansoor Raza Mirza
ESMO23Gynækologisk cancer Play the Video
Karin Brochstedt Dieperink

Sygeplejerskens centrale rolle i behandlingen af senfølger

/ Karin Dieperink
ESMO23 Play the Video
Shannon Westin

Insights on DUO-E Trial: Advancing Endometrial Cancer Treatment with Olaparib

/ Shannon Westin
ESMO23Gynækologisk cancer Play the Video
Jaffer Ajani

Findings from the SPOTLIGHT Study Demonstrate the Power of the New Biomarker Claudin-18.2.

/ Jaffer Ajani
ESMO23Gastrointestinal cancer Play the Video
Arlene Siefker-Radtke

Urothelial Cancer: One Step Forward to Understand How to Combine and Sequence Treatments Against Novel Targets

/ Arlene O. Siefker-Radtke
ESMO23Blærecancer Play the Video
Hent flere

ESMO 2022

Postoperative komplikationer forringer overlevelse ved brystkræft men ikke tilbagefaldsrisikoen

/ Onkologi / Kasper Kjærgaard

Bladder Cancer: The Danish TOMBOLA Shows Practice Changing Results

/ Onkologi / BestPractice Nordic

Another Step Forward for Breast Cancer Treatment

/ Onkologi / BestPractice Nordic

ESMO 2024: Presentations and Perspectives of New Data at Norwegian Evening

/ Almen praksis / BestPractice Nordic

ESMO 2024: Presentations and Perspectives of New Data at Danish Evening

/ Onkologi / Jan Andreasen
Se oversigt

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Onkologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Onkologi / Jon Amund Kyte

The clinical value of circulating tumor DNA in bladder and renal cancer

/ Onkologi / Lars Dyrskjøt Andersen
Se oversigt

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann
Se oversigt

ESMO 2021

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Onkologi / Eric Pujade-Lauraine

Global consensus: Management of epithelioid hemangioendothelioma

/ Onkologi / Silvia Stacchiotti

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Onkologi / Eric Pujade-Lauraine

HER2-positiv brystcancer – fremtidige behandlingsmuligheder

/ Onkologi / Alan Celik

Opdatering på CheckMate 649-studiet

/ Onkologi / Lene Bæksgaard
Se oversigt

High-risk factors in patients with advanced ovarian cancer impact survival

/ Onkologi / Dana Chase

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

/ Onkologi / Ma Pilar Barretina-Ginesta

Klinisk perspektivering af COAST-studiet for patienter med metastatisk ikke-operable stadie III ikke-småcellet lungecancer

/ Onkologi / Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Onkologi / Roy S. Herbst

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

/ Onkologi / Camillo Porta
Se oversigt

Promising clinical results for heavily pretreated patients with colorectal cancer

/ Onkologi / Jared Weiss

Perspective of first line immune therapy of non-small-cell lung cancer

/ Onkologi / Ahmet Sezer

Dansk real-life studie viser, at prognosen for malignt melanom med hjernemetastaser er forbedret siden 2015

/ Onkologi / Sidsel Pedersen

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

/ Onkologi / Nir Peled

Immunterapi har positiv effekt på ubehandlede hjernemetastaser ved ikke-småcellet lungecancer

/ Onkologi / Birgitte Bjørnhart
Se oversigt

Back to top